2 completed, 1 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Nystagmus, Pathologic: new trials by email Literature Review of Nystagmus, Pathologic trials Research Report on Nystagmus, Pathologic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus Neramexane mesylate - Nystagmus, Congenital, Nystagmus, Acquired | Phase 2 | Terminated | Merz Pharmaceuticals GmbH | 48 | 2009-05-01 | 2010-07-01 |
| Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus Neramexane mesylate - Nystagmus, Congenital Idiopathic, Nystagmus, Acquired | Phase 2 | Completed | Merz Pharmaceuticals GmbH | 48 | 2008-05-01 | 2009-11-26 |
| Eye Muscle Surgery to Treat Congenital Nystagmus horizontal muscles of the eye will be cut and then reattached in the same position - Nystagmus | Phase 2 | Completed | National Eye Institute (NEI) | 15 | 1999-08-01 | 2008-03-04 |
Nystagmus, Congenital (2) · Multiple Sclerosis (1)
Cranial Nerve Diseases (3) · Eye Diseases (3) · Nervous System Diseases (3) · Ocular Motility Disorders (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Infant, Newborn, Diseases (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1)
Merz Pharmaceuticals GmbH (2) · National Eye Institute (NEI) (1)
United Kingdom (2) · United States (1)